Jun 15 2026 09:55 PM EST

When the White Coat Fades: Why Doximity’s Digital Doctor Empire Lost Its Pulse

Doximity, Inc. (NYSE: DOCS) watched its reputation as the “LinkedIn for doctors” morph from Wall Street’s most beloved healthtech to a cautionary tale, as its share price collapsed by 55.1% in just six months—and a staggering 64.2% over the past year. What sent the pulse oximeter plunging on this digital doctor network, beloved by 80% of U.S. physicians and envied for its cash-rich model?

The Growth Comedown: From IV Drip to Trickle

For years, the market mainlined double-digit revenue growth from Doximity. But in 2026, the adrenaline wore off. Quarterly revenue increases slowed to a mere 5% in Q4, while full-year growth limped to 13%—down from 20% just one year earlier. Management’s forecast for FY2027 landed with a thud: an anemic 4% midpoint. These are not the numbers that make a market swoon; they’re the drip of a company outgrowing its own story.

Profit margins, once Doximity’s badge of invincibility, started to fray. Net income margin sank from 39.1% in 2025 to 30.4% in 2026, as the company poured cash into AI R&D and brand marketing, chasing a new narrative for the Street. Free cash flow remained robust at $317 million, but investors began to question if the golden goose was molting.

The Pharma Freeze: Budgets in the Deep Chill

Doximity’s core lifeblood—digital advertising and engagement solutions sold to pharmaceutical giants—froze over as industry ad budgets caught a regulatory and macroeconomic frostbite. In 2026, sixteen of the top twenty pharma clients delayed spending, rattled by the “Most Favored Nation” drug pricing negotiations with the White House and looming policy shifts from the 2024 U.S. elections. Hospital systems, battered by reimbursement compression, tightened hiring and ad spend. The result? Doximity’s biggest clients, who account for more than 55% of revenue, became both a blessing and a curse—exposing the company to the chill of industry cyclicality.

The AI Fever: Big Bets, Small Payoff (For Now)

If the last bull market was about growth at all costs, the new mantra is profitability with proof. Doximity’s feverish investment in AI—acquisitions like Pathway Medical for $63 million, launches of Scribe and DocsGPT, and expanded compute infrastructure—delivered record engagement (over 800,000 active prescribers and tripling AI tool usage), but little near-term revenue. Despite 140 health systems on the Clinical AI Suite, management confessed that AI’s revenue impact would be “minimal” in 2026 and guidance for 2027 showed little acceleration. The result? Margin compression—gross margin fell to 89% in Q4—and a market that’s grown weary of “jam tomorrow.”

Insider Shivers and Boardroom Blues

If numbers don’t lie, insider behavior whispers the subtext. In the run-up to and aftermath of Doximity’s Q4 earnings, C-suite and directors sold shares worth over $150 million. The company tried to soothe nerves with a $500 million buyback, but with no open-market insider buying and a delayed permanent CFO appointment until after the stock collapse, the Street was not convinced. Litigation—class actions alleging misrepresentation of user metrics—added a legal chill, even as most claims were dismissed.

Digital Health’s Hangover: The Macro Prescription

Doximity’s malaise is not a solitary diagnosis. The entire U.S. digital health sector has been hit by a wave of skepticism as investors pivot from “grow at any cost” to “show me the money.” Tech multiples deflated, with Doximity’s own forward P/E falling from 40x to 20x in one year—now at a discount to its own historic average and healthtech peers. As venture funding shifted to consumer and workflow plays, and regulatory scrutiny around AI and data privacy mounted, the market began to reprice risk and future promises.

The 2025 Budget Reconciliation Act’s $1 trillion in health spending cuts, Medicaid work requirements, and ACA premium hikes all threaten to squeeze hospital and pharma budgets further—casting a long shadow over Doximity’s revenue base for 2026 and beyond.

The Final Diagnosis: Market Trust is the Hardest Drug

Doximity’s balance sheet remains fortress-like—$749 million in cash, zero debt, and 55% adjusted EBITDA margin. But with shares trading near a 52-week low at $25.55, down from highs of $76.51, and short interest climbing to 10% of float, investors are asking for more than clinical engagement—they want earnings resuscitation and AI-driven growth that’s real, not just theoretical.

The prescription for Doximity? Prove that AI can revive not just workflow, but the top line. Until then, the white coat will hang in the closet—waiting for the next pulse.